Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, 300060 Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, 300060 Tianjin, China.
Biomed Res Int. 2020 Oct 8;2020:8965459. doi: 10.1155/2020/8965459. eCollection 2020.
Reports increasingly suggest that Chinese herbal medicine (CHM) has been used to treat ovarian cancer (OvCa) with a good curative effect; however, the molecular mechanisms underlying CHM are still unclear. In this retrospective study, we explored CHM's molecular targets for the treatment of OvCa based on clinical data and network pharmacology. We used the Kaplan-Meier method and Cox regression analysis to verify the survival rate of 202 patients with CHM-treated OvCa. The association between CHM and survival time was analyzed by bivariate correlation. A target network of CHM active ingredients against OvCa was established via network pharmacology. Cox regression analysis showed that CHM is an independent favorable prognostic factor. The median survival time was 91 months in the CHM group and 65 months in the non-CHM group. The survival time of FIGO stage III patients in the two groups was 91 months and 52 months, and the median survival period of FIOG stage IV patients was 60 months and 22 months, respectively ( < 0.001). Correlation analysis demonstrated that 12 herbs were closely associated with prognosis, especially in regard to the long-term benefits. Bioinformatics analysis indicated that the anti-OvCa activity of these 12 herbs occurs mainly through the regulation of apoptosis-related protein expression, which promotes OvCa cell apoptosis and inhibits OvCa development. They also regulate the progress of OvCa treatment by promoting or inhibiting protein expression on the p53 signaling pathway and by inhibiting the NF-B signaling pathway by directly inhibiting NF-B.
报告越来越多地表明，中草药（CHM）已被用于治疗卵巢癌（OvCa），疗效良好；然而，CHM 的分子机制仍不清楚。在这项回顾性研究中，我们基于临床数据和网络药理学探讨了 CHM 治疗 OvCa 的分子靶点。我们使用 Kaplan-Meier 方法和 Cox 回归分析验证了 202 名接受 CHM 治疗的 OvCa 患者的生存率。通过双变量相关性分析 CHM 与生存时间的关系。通过网络药理学建立了 CHM 活性成分针对 OvCa 的靶标网络。Cox 回归分析表明，CHM 是一个独立的有利预后因素。CHM 组的中位生存时间为 91 个月，非 CHM 组为 65 个月。FIGO 分期 III 期患者在两组中的生存时间分别为 91 个月和 52 个月，FIGO 分期 IV 期患者的中位生存期分别为 60 个月和 22 个月（<0.001）。相关性分析表明，12 种草药与预后密切相关，尤其是在长期获益方面。生物信息学分析表明，这 12 种草药的抗 OvCa 活性主要通过调节凋亡相关蛋白的表达来发挥作用，促进 OvCa 细胞凋亡，抑制 OvCa 发展。它们还通过直接抑制 NF-B 来抑制 NF-B 信号通路，从而促进或抑制 p53 信号通路中的蛋白表达，从而调节 OvCa 治疗的进展。
